logo
  

Gilead: Week 48 Findings Underscore Efficacy Of Bulevirtide For Treatment Of Chronic HDV

Gilead Sciences, Inc. (GILD) reported week 48 results from the phase 3 trial evaluating Hepcludex or bulevirtide for the treatment of chronic hepatitis delta virus infection. The company said these data reinforce the clinical utility of bulevirtide as monotherapy for the treatment of chronic hepatitis delta virus. The data showed the positive impact of bulevirtide on patient-reported outcomes. The safety profile of bulevirtide at week 48 is consistent with prior reports.

Bulevirtide was granted Conditional Marketing Authorization by the European Commission and is an investigational agent in the U.S. and outside of the European Economic Area. Bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT